John F. Barrett
John F. Barrett has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Michael J. Pucci
Achillion Pharmaceuticals, New Haven, Connecticut, USA
2 shared publications - Thomas J. Dougherty
AstraZeneca Pharmaceuticals LP
2 shared publications - Thomas J. Dougherty
Merck Research Laboratories, Rahway, NJ, USA
2 shared publications Cheryl A Ferraro
Bristol-Myers Squibb Co., Department 104, Microbiology, 5 Research Parkway, Wallingford, Connecticut 06492, USA. Tel: +1 203 677 6258; Fax: +1 203 677 6771
1 shared publicationDaniel B Davison
Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT 06492, USA
1 shared publicationDanielle Beaulieu
Bristol-Myers Squibb Co., Department 104, Microbiology, 5 Research Parkway, Wallingford, Connecticut 06492, USA. Tel: +1 203 677 6258; Fax: +1 203 677 6771
1 shared publication
Latest Publications
- 1 August 2005
- Vol. 6 (8) , 781-90
Recent developments in glycopeptide antibacterials.
The glycopeptide class of antibiotics, namely vancomycin and teicoplanin, are intravenously administered in the hospital setting for the treatment of the most severe of Gram-positive infections. Although a mainstay of the hospital formulary for over four decades, the rise of increasingly frequent high-level vancomycin resistance in enterococci and low-level resistance in staphylococci (as well as a few high-level vancomycin resistance cases) has highlighted the need for the identification of naturally occurring and semi-synthetically modified glycopeptide derivatives that have antibacterial activity against these resistant strains. Among the leading development candidates are dalbavancin, oritavancin, telavancin and ramoplanin, each of which provides a unique microbiological and pharmacological profile to fill an important unmet medical need.
- 1 August 2005
- Vol. 6 (8) , 781-90
Recent developments in glycopeptide antibacterials.
The glycopeptide class of antibiotics, namely vancomycin and teicoplanin, are intravenously administered in the hospital setting for the treatment of the most severe of Gram-positive infections. Although a mainstay of the hospital formulary for over four decades, the rise of increasingly frequent high-level vancomycin resistance in enterococci and low-level resistance in staphylococci (as well as a few high-level vancomycin resistance cases) has highlighted the need for the identification of naturally occurring and semi-synthetically modified glycopeptide derivatives that have antibacterial activity against these resistant strains. Among the leading development candidates are dalbavancin, oritavancin, telavancin and ramoplanin, each of which provides a unique microbiological and pharmacological profile to fill an important unmet medical need.
- 22 April 2005
- Published by Informa Healthcare in Expert Opinion on Therapeutic Targets
- Vol. 9 (2) , 253-265
MRSA – what is it, and how do we deal with the problem?
Methicillin-resistant Staphylococcus aureus (MRSA) has become a serious nosocomial pathogen, and more recent reports in the scientific literature underscore the potential issues with emerging community-MRSA. MRSA is reported to be involved in > 50% of hospital S. aureus infections, more in the intensive care unit (ICU) than the non-ICU, and increases in multi-drug resistant MRSA and increasingly virulent MRSA have been reported. Together with its broad-based β-lactam resistance, MRSA often possesses a multi-drug resistance genotype, including cephalosporins, aminoglycosides, fluoroquinolones, and macrolide resistances. MRSA has now emerged as the predominant nosocomial Gram-positive pathogen, and it has a high rate of morbidity and mortality. Action must be taken to contain and eradicate MRSA through a combination of infection control, the development of novel anti-MRSA agents, develop-ment of vaccines and other non-traditional approaches of interven-tion.
- 22 April 2005
- Published by Informa Healthcare in Expert Opinion on Therapeutic Targets
- Vol. 9 (2) , 253-265
MRSA – what is it, and how do we deal with the problem?
Methicillin-resistant Staphylococcus aureus (MRSA) has become a serious nosocomial pathogen, and more recent reports in the scientific literature underscore the potential issues with emerging community-MRSA. MRSA is reported to be involved in > 50% of hospital S. aureus infections, more in the intensive care unit (ICU) than the non-ICU, and increases in multi-drug resistant MRSA and increasingly virulent MRSA have been reported. Together with its broad-based β-lactam resistance, MRSA often possesses a multi-drug resistance genotype, including cephalosporins, aminoglycosides, fluoroquinolones, and macrolide resistances. MRSA has now emerged as the predominant nosocomial Gram-positive pathogen, and it has a high rate of morbidity and mortality. Action must be taken to contain and eradicate MRSA through a combination of infection control, the development of novel anti-MRSA agents, develop-ment of vaccines and other non-traditional approaches of interven-tion.
- 1 December 2004
- Published by Informa Healthcare in Expert Opinion on Therapeutic Targets
- Vol. 8 (6) , 515-519
MRSA: status and prospects for therapy? An evaluation of key papers on the topic of MRSA and antibiotic resistance
Methicillin-resistant Staphylococcus aureus (MRSA) is a serious nosocomial pathogen, and a related community-sourced MRSA is emerging. MRSA has evolved to become the major S. aureus phenotype in the hospital, emerging from just 30 to over 60% of the S. aureus population over the past 15 years. Together with its β-lactam resistance, MRSA possesses multi-drug resistance genotype, including quinolones, macrolides and sulfonamides. MRSA has now emerged as the predominant nosocomial Gram-positive pathogen, and it has a high rate of mortality. Action must be taken to contain and eradicate MRSA through a combination of infection control and the development of novel anti-MRSA agents and vaccines.
- 1 December 2004
- Published by Informa Healthcare in Expert Opinion on Therapeutic Targets
- Vol. 8 (6) , 515-519
MRSA: status and prospects for therapy? An evaluation of key papers on the topic of MRSA and antibiotic resistance
Methicillin-resistant Staphylococcus aureus (MRSA) is a serious nosocomial pathogen, and a related community-sourced MRSA is emerging. MRSA has evolved to become the major S. aureus phenotype in the hospital, emerging from just 30 to over 60% of the S. aureus population over the past 15 years. Together with its β-lactam resistance, MRSA possesses multi-drug resistance genotype, including quinolones, macrolides and sulfonamides. MRSA has now emerged as the predominant nosocomial Gram-positive pathogen, and it has a high rate of mortality. Action must be taken to contain and eradicate MRSA through a combination of infection control and the development of novel anti-MRSA agents and vaccines.
- 1 June 2004
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 13 (6) , 715-721
Antibacterial Drug Discovery & Development Summit
Over 100 senior researchers and managers from academic and industrial research organisations attended this 2-day annual international discovery summit on antibacterial R&D. A number of firms, particularly biotechnology firms, presented compounds that are advancing through clinical development. In addition, areas for basic research and development included metallo-beta-lactamases, ribosomal structural studies and phage-selected targets were described.
- 1 June 2004
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 13 (6) , 715-721
Antibacterial Drug Discovery & Development Summit
Over 100 senior researchers and managers from academic and industrial research organisations attended this 2-day annual international discovery summit on antibacterial R&D. A number of firms, particularly biotechnology firms, presented compounds that are advancing through clinical development. In addition, areas for basic research and development included metallo-beta-lactamases, ribosomal structural studies and phage-selected targets were described.
- 1 July 2003
- Vol. 6 (7) , 639-42
American Society for Microbiology-103rd General Meeting. 18-22 May 2003, Washington DC, USA.
- 1 July 2003
- Vol. 6 (7) , 639-42
American Society for Microbiology-103rd General Meeting. 18-22 May 2003, Washington DC, USA.
- 1 October 2002
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 2 (5) , 485-486
Anti-infectives
- 1 October 2002
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 2 (5) , 485-486
Anti-infectives
- 1 December 2001
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 45 (12) , 3660-3662
Mechanism of Action of the Des-F(6) Quinolone BMS-284756 Measured by Supercoiling Inhibition and Cleavable Complex Assays
BMS-284756 (T-3811ME), a novel des-F(6) quinolone, was tested in the supercoiling inhibition and cleavable complex assays against Escherichia coli DNA gyrase, a target of quinolones. The results suggest that BMS-284756 has the same mechanism of action against DNA gyrase as other quinolones and a similar level of potency.
- 1 December 2001
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 45 (12) , 3660-3662
Mechanism of Action of the Des-F(6) Quinolone BMS-284756 Measured by Supercoiling Inhibition and Cleavable Complex Assays
BMS-284756 (T-3811ME), a novel des-F(6) quinolone, was tested in the supercoiling inhibition and cleavable complex assays against Escherichia coli DNA gyrase, a target of quinolones. The results suggest that BMS-284756 has the same mechanism of action against DNA gyrase as other quinolones and a similar level of potency.
- 24 February 2001
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 10 (2) , 343-351
ABT-773: a new ketolide antibiotic
ABT-773 is a new semisynthetic derivative of erythromycin A, the ketolide class of broad spectrum antibacterial agents, in Phase II development by Abbott. With good broad spectrum activity against Gram-positive, some Gram-negative organisms and intracellular bacteria, ABT-773 is being developed as a respiratory agent. Structural changes in the ketolide class agents such as ABT-773 provides expanded activity in vitro against macrolide-resistant strains of Streptococcus pneumoniae and improved activity against MLS(B) (macrolide-lincosamide-streptogramin) constitutive expressing streptococci.
- 24 February 2001
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 10 (2) , 343-351
ABT-773: a new ketolide antibiotic
ABT-773 is a new semisynthetic derivative of erythromycin A, the ketolide class of broad spectrum antibacterial agents, in Phase II development by Abbott. With good broad spectrum activity against Gram-positive, some Gram-negative organisms and intracellular bacteria, ABT-773 is being developed as a respiratory agent. Structural changes in the ketolide class agents such as ABT-773 provides expanded activity in vitro against macrolide-resistant strains of Streptococcus pneumoniae and improved activity against MLS(B) (macrolide-lincosamide-streptogramin) constitutive expressing streptococci.
- 1 August 2000
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 9 (8) , 1707-1709
Antimicrobial resistance - why do we have it and what can we do about it?
- 1 August 2000
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 9 (8) , 1707-1709
Antimicrobial resistance - why do we have it and what can we do about it?
- 1 August 2000
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 9 (8) , 1907-1922
100th American Society for Microbiology Annual Meeting
The 100th ASM Annual Meeting, attended by approximately 10,000 delegates, continued the trend of concentrating on bacteria and antibacterial therapy, mixed with genomics and a diverse number of additional topics. Of the various marketable drug classes, the quinolones received attention with respect to susceptibility studies and several drug comparison studies. New marketable drugs were also of interest, especially given the reservoirs of resistance presented by several speakers. Drugs in development include the antibacterial daptomycin and protegrins and the antifungal lipodepsinonapeptides and echinocandins, to name a few. It is still unclear whether or not antibiotic treatment regimens for Chlamydia pneumonia will he necessary, as association of this bacteria with several chronic diseases, such as atherosclerosis and asthma, was discussed. The development of novel antibiotics was highlighted and the potential role that microbial genomics technology could play was a recurring theme. In fact, a number of symposia treated the increasingly popular topic of genomics in a variety of themes, including phenotyping arrays, transcriptional profiling, proteomics, expression profiling, genome sequencing, target areas or essentiality of genes via gene knockout systems, the role of genomics in pharmaceutical development and fungal genomics. Similarly, genomics plays a role in developing a deeper appreciation for classical areas of interest in microbial physiology, such as gene regulation, cell division, fatty acid biosynthesis, DNA replication and cell signalling. Even in the bio-inorganic field of study in microbial metabolite activation, genomics plays a role. The sequencing of the large gene clusters of the auxiliary proteins necessary to synthesise or activate the metallo-proteins provided insights into the mechanisms of activation of these microbial enzymes, including the genes for the nif gene cluster in Azotobacter vinelandii, the urease from Kiebsiella aerogenes and the three hydrogenases in Ralstonia eutropha.
- 1 August 2000
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 9 (8) , 1907-1922
100th American Society for Microbiology Annual Meeting
The 100th ASM Annual Meeting, attended by approximately 10,000 delegates, continued the trend of concentrating on bacteria and antibacterial therapy, mixed with genomics and a diverse number of additional topics. Of the various marketable drug classes, the quinolones received attention with respect to susceptibility studies and several drug comparison studies. New marketable drugs were also of interest, especially given the reservoirs of resistance presented by several speakers. Drugs in development include the antibacterial daptomycin and protegrins and the antifungal lipodepsinonapeptides and echinocandins, to name a few. It is still unclear whether or not antibiotic treatment regimens for Chlamydia pneumonia will he necessary, as association of this bacteria with several chronic diseases, such as atherosclerosis and asthma, was discussed. The development of novel antibiotics was highlighted and the potential role that microbial genomics technology could play was a recurring theme. In fact, a number of symposia treated the increasingly popular topic of genomics in a variety of themes, including phenotyping arrays, transcriptional profiling, proteomics, expression profiling, genome sequencing, target areas or essentiality of genes via gene knockout systems, the role of genomics in pharmaceutical development and fungal genomics. Similarly, genomics plays a role in developing a deeper appreciation for classical areas of interest in microbial physiology, such as gene regulation, cell division, fatty acid biosynthesis, DNA replication and cell signalling. Even in the bio-inorganic field of study in microbial metabolite activation, genomics plays a role. The sequencing of the large gene clusters of the auxiliary proteins necessary to synthesise or activate the metallo-proteins provided insights into the mechanisms of activation of these microbial enzymes, including the genes for the nif gene cluster in Azotobacter vinelandii, the urease from Kiebsiella aerogenes and the three hydrogenases in Ralstonia eutropha.